Stage-dependent BDNF serum concentrations in Alzheimer's disease

Area of Science:

• Neuroscience
• Biochemistry
• Gerontology

Background:

• Alzheimer's disease (AD) involves cognitive decline and neuronal loss, with emerging evidence implicating brain-derived neurotrophic factor (BDNF).
• BDNF is crucial for neuronal maintenance, synaptic plasticity, and structural integrity in the adult brain.

Purpose of the Study:

• To investigate serum and cerebrospinal fluid (CSF) concentrations of BDNF in patients with varying stages of Alzheimer's disease compared to healthy controls.
• To assess the relationship between BDNF levels and disease severity, as measured by the Mini-Mental State Examination (MMSE) score.

Main Methods:

• A pilot study involving 30 Alzheimer's disease patients and 10 age-matched controls.
• Patients were categorized into early (MMSE ≥ 21) and severe (MMSE < 21) stages of AD.
• BDNF concentrations were measured in serum and CSF samples.

Main Results:

• Significantly increased serum BDNF concentrations were observed in early-stage AD patients compared to severe AD patients and healthy controls.
• Serum BDNF levels in all AD patients showed a significant positive correlation with MMSE scores.
• BDNF levels in CSF samples were below the assay's detection limit in both AD patients and controls.

Conclusions:

• Elevated serum BDNF in early AD may represent a compensatory repair mechanism and potentially aid in beta-amyloid (Abeta) degradation.
• Decreasing BDNF levels with disease progression correlate with dementia severity, suggesting a lack of trophic support and increased Abeta accumulation.
• BDNF warrants further investigation as a potential biomarker for AD diagnosis and therapeutic monitoring.